NC
TGTX icon

NinePointTwo Capital’s TG Therapeutics TGTX Stock Holding History

NinePointTwo Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$669K Buy
+39,170
New +$455K 0.27% 28
2023
Q3 		– Sell
-10,170
Closed -$252K – 320
2023
Q2 		$252K Sell
10,170
-3,711
-27% -$95.9K 0.1% 132
2023
Q1 		$208K Buy
+13,881
New +$211K 0.08% 214

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $94.8B AUM 24.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

NinePointTwo Capital's TGTX Position: Q4 2023 in Review

NinePointTwo Capital opened a new position in TG Therapeutics (TGTX) in Q4 2023: 39,170 shares worth $669K. The stake represents 0.27% of the portfolio and ranks #28 among its holdings. This is a return to the name: NinePointTwo Capital previously reported a position in TGTX as recently as Q2 2023.

NinePointTwo Capital first reported a position in TGTX in Q1 2023 and has held it in 3 quarters since. 235 funds tracked by Wall St. Rank hold TGTX as of Q4 2023.

  • NinePointTwo Capital held 39,170 shares of TG Therapeutics worth $669K as of Q4 2023.
  • TG Therapeutics was a new NinePointTwo Capital position in Q4 2023.
  • TG Therapeutics made up 0.27% of NinePointTwo Capital's portfolio in Q4 2023, its #28 holding.
  • NinePointTwo Capital first reported a position in TG Therapeutics in Q1 2023 and has held it in 3 quarters since.
  • 235 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2023.

Based on NinePointTwo Capital's 13F filing for Q4 2023, filed 14 Feb 2024.